Capecitabine is mainly used in the treatment of colorectal cancer, breast cancer, stomach cancer, esophageal cancer and other malignant tumors. Capecitabine can be used as adjuvant chemotherapy for colon cancer or combined with other drugs for the first-line treatment of metastatic colorectal cancer, as well as for the treatment of breast cancer, etc. Capecitabine is not a cure for cancer, but can be used in combination with surgery or radiotherapy for radical treatment. Capecitabine is not a cure for cancer, but can be used in combination with surgery or radiotherapy for radical or adjuvant treatment. In a clinical trial of adjuvant chemotherapy for colon cancer, the 5-year disease-free survival rate of patients was 59.1%, with good clinical efficacy. Common adverse reactions include anorexia, diarrhea, vomiting, dermatitis, drowsiness, fatigue, etc. It is contraindicated for those who are allergic to this product and those with severe renal impairment. The above is only part of the clinical trial data of Capecitabine. It is recommended to use the drug strictly under the guidance of a physician and to build up confidence in the fight against the disease.